[1]梁奇明,连立飞,许峰,等.药源性帕金森综合征的临床分型及特征[J].卒中与神经疾病杂志,2022,29(05):405-409.[doi:10.3969/j.issn.1007-0478.2022.05.002]
　Liang Qiming,Lian Lifei,Xu Feng,et al.Clinical features in the different subtypes of drug-induced Parkinsonism[J].Stroke and Nervous Diseases,2022,29(05):405-409.[doi:10.3969/j.issn.1007-0478.2022.05.002]
点击复制

药源性帕金森综合征的临床分型及特征()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第29卷
期数:
2022年05期
页码:
405-409
栏目:
论著
出版日期:
2022-10-10

文章信息/Info

Title:
Clinical features in the different subtypes of drug-induced Parkinsonism
文章编号:
1007-0478(2022)05-0405-05
作者:
梁奇明; 连立飞; 许峰; 胡琦
430030 武汉，华中科技大学同济医学院附属同济医院神经内科（梁奇明 连立飞 许峰），全科医学科［胡琦（通信作者）］
Author(s):
Liang Qiming;  Lian Lifei;  Xu Feng;  et al.
Department of Neurology, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan 430030
关键词:
药源性帕金森综合征; 帕金森病; 鉴别诊断
Keywords:
Drug-induced parkinsonism; Parkinson's disease; Differential diagnosis
分类号:
R742.5
DOI:
10.3969/j.issn.1007-0478.2022.05.002
文献标志码:
A
摘要:
探讨药源性帕金森综合征（Drug-induced parkinsonism, DIP）的临床分型及临床表现。 方法 分析2017年1月-2018年12月于本院收集的29例DIP患者，根据停用致病药物1年后病情恢复程度不同将DIP患者分为可逆性DIP(Reversible DIP, rDIP)和持续性DIP(Persistent DIP, pDIP)，分析两者临床特征。 结果 2组患者均以老年患者为主，女性多见；2组在症状出现前服用致病药物时间、就诊时症状已持续时间、致病药物构成均也无明显差异；同时分别在就诊时和停药1年后对rDIP组患者与pDIP组患者行MDS-UPDRS评分显示，2组症状好转率和左右侧肢体不对称指数均有显著性差异（P<0.05），而2组在上肢症状分数和占比、下肢症状分数和占比、非运动症状等方面均无显著性差异（P>0.05）。 结论 rDIP和pDIP组患者的临床特征和预后存在差异，左右侧肢体症状不对称指数有助于鉴别两者。
Abstract:
Objective To investigate the clinical classification of drug-induced parkinsonism (DIP). Methods 29 patients with DIP were included in this study. The DIP patients were subtyped to reversible DIP (rDIP) and persistent DIP (pDIP) according to the recovery ratio. Clinical features of rDIP and pDIP were analyzed. Results DIP in both subtypes predominantly occurs in older people and women. There were no statistically significant differences in age, gender, duration of drug exposure, duration of parkinsonism, and baseline MDS-UPDRS III score values between the pDIP and rDIP groups. At a 12-month follow-up visit, MDS-UPDRS III score values showed that the recovery ratio and asymmetry index in rDIP are significantly different from those in pDIP. However, there were no significant differences in the upper limb score/ratio, the lower limb score/ratio, and non-motor symptoms. Conclusion There are distinct differences in clinical features and prognosis between rDIP and pDIP. The asymmetry index is a helpful item to make a differential diagnosis.

参考文献/References:

[1] Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older People[J]. Postgrad Med J, 2009, 85(14): 322-326.
[2] [JP2]López-Sendón J, Mena MA, De Yébenes JG. Drug-induced parkinsonism[J]. Expert Opin Drug Saf, 2013, 12(4): 487-496.
[3] López-Sendón JL, Ma MA, De Yébenes JG. Drug-induced parkinsonism in the elderly: incidence, management and prevention[J]. Drugs Aging, 2012, 29(2): 105-118.
[4] Morley JF, Pawlowski SM, Kesari A, et al. Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism[J]. Parkinsonism Relat Disord, 2014, 20(7): 738-742.
[5] Tinazzi M, Antonini A, Bovi T, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism[J]. J Neurol, 2009, 256(6): 910-915.
[6] Shin HW, Kim JS, Oh M, et al. Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography[J]. Neurol Sci, 2015, 36(2): 269-274.
[7] De GS, Montastruc F, Carvajal A, et al. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database[J]. Parkinsonism Relat Disord, 2020, 70: 55-59.
[8] Han S, Kim S, Kim H, et al. Prevalence and incidence of Parkinson's disease and drug-induced parkinsonism in Korea[J]. BMC Public Health, 2019, 19(1): 1328.
[9] Shin HW, Chung SJ. Drug-induced parkinsonism[J]. J Clin Neurol, 2012, 8(1):15-21.
[10] Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Drug-induced parkinsonism:a review of 17 years'experience in a regional pharmacovigilance center in France[J]. Mov Disord, 2011, 26(12): 2226-2231.
[11] Costa KM. The effects of aging on substantia nigra dopamine neurons[J]. J Neurosci, 2014, 34(46): 15133-15134.
[12] Byun JH, Cho H, Kim YJ, et al. Trends in the prevalence of Drug-Induced parkinsonism in Korea[J]. Yonsei Med J, 2019, 60(8): 760-767.
[13] Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations[J]. Drugs Aging, 2000, 17(5): 363-384.
[14] Munhoz RP, Bertucci FD, Teive HA. Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype[J]. Neurol Sci, 2017, 38(2): 319-324.
[15] Lim TT, Ahmed A, Itin I, et al. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?[J]. Int J Neurosci, 2013, 123(3): 170-174.
[16] Factor SA, Burkhard PR, Caroff S, et al. Recent developments in drug-induced movement disorders: a mixed picture[J]. Lancet Neurol, 2019, 18(9): 880-890.
[17] Erickson JD, Eiden LE, Hoffman BJ. Expression cloning of a reserpine-sensitive vesicular monoamine transporter[J]. Proc Natl Acad Sci U S A, 1992, 89(22): 10993-10997.
[18] García Ruiz PJ, Ma MA, Peafiel N, et al. Cinnarizine-induced parkinsonism in primates[J]. Clin Neuropharmacol, 1992, 15(2): 152-154.
[19] Meredith GE, Switzer R3, Napier TC. Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum[J]. Brain Res, 2004, 995(1): 14-22.
[20] Fà M, Mereu G, Ghiglieri V, et al. Electrophysiological and pharmacological characteristics of nigral dopaminergic neurons in the conscious, head-restrained rat[J]. Synapse, 2003, 48(1): 1-9.
[21] Iwahashi K, Anemo K, Nakamura K, et al. Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism[J]. Neuropsychobiology, 2001, 44(3): 126-128.
[22] Fereshtehnejad SM, Dawson BK, Pelletier A, et al. Long lag between drug-induced parkinsonism and idiopathic parkinson's disease in idiopathic REM sleep behavior disorder[J]. Mov Disord Clin Pract, 2018, 5(2): 203-205.
[23] Honer WG, Kopala LC, Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness[J]. J Psychopharmacol, 2005, 19(3): 277-285.
[24] Olivares RJ, Arjona PA, Barrero HF, et al. Utility of transcranial sonography in the diagnosis of drug-induced parkinsonism: a prospective study[J]. European Journal of Neurology, 2013, 20(11): 1451-1458.
[25] Lee PH, Kim JS, Shin DH, et al. Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism[J]. J Neurol Neurosurg Psychiatry, 2006, 77(3): 372-374.

相似文献/References:

[1]宋爱民,易琼,朱梦婷,等.川芎嗪添加治疗帕金森病的临床疗效观察[J].卒中与神经疾病杂志,2015,22(01):25.
[2]陈敏,陈艳红,潘庆敏,等.葡萄糖脑苷酯酶与帕金森病a-突触核蛋白的关系研究进展[J].卒中与神经疾病杂志,2015,22(01):55.
[3]孟兰霞,刘聪聪,张振涛.细菌CsgA蛋白促进α-Syn聚集[J].卒中与神经疾病杂志,2022,29(05):401.[doi:10.3969/j.issn.1007-0478.2022.05.001]
　Men Lanxia,Liu Congcong,Zhang Zhentao.Bacterial protein CsgA accelerates α-synuclein aggregation[J].Stroke and Nervous Diseases,2022,29(05):401.[doi:10.3969/j.issn.1007-0478.2022.05.001]

更新日期/Last Update: 2022-10-10